Sunesis Pharmaceuticals, Inc. Message Board

About 200 million O/S when fully diluted-The company intend to complete phase 3 of Voreloxin with it. Hence the reason they said enough capital for it.

Sales of Voreloxin $300 million current (very conservative because much more babyboomers will enter the age over time)

* Total AML market is currently $900 million in the US alone and considering Voreloxin's first-in-class status and the best-in-class in tiny mortality (3% in 30 days) and longest survivability (over 7 months and 12 or 20 patients are still alive-!!!)

Gross margin 70% (very conservative because this sector it can reach 80% to 90%)

Operating expenses for $50 mil.R&D, marketing, other drug trials, etc (more than sufficient-the current is only $22 mil. per year)

That makes Operating Income about $160 million. P/E ratio about 20 (very conservative when GENZ has P/E 34).
That makes potential market cap of about $3.2 Billion.

Current market cap is:
1. $30 million for 57 million O/S
2. $100 million for 200 million O/S if fully diluted and only if.

Let's assume that alone the phase 3 trial all the tranches are exercised and fully diluted-company has this resources, comfortable to complete phase 3.

We are looking at 3200% increase when fully diluted and over 10k% increase if not diluted.

That's close to $20.00 per share when fully diluted in 3 years!